Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
28.52
+0.36 (1.28%)
May 4, 2026, 4:00 PM EDT - Market closed
Immunocore Holdings Revenue
In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth. Immunocore Holdings had revenue of $104.48M in the quarter ending December 31, 2025, with 24.30% growth.
Revenue (ttm)
$400.02M
Revenue Growth
+28.95%
P/S Ratio
3.62
Revenue / Employee
$763,389
Employees
524
Market Cap
1.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 75.07M | 43.05% |
| Dec 31, 2022 | 174.36M | 137.88M | 377.91% |
| Dec 31, 2021 | 36.48M | -4.69M | -11.39% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Iovance Biotherapeutics | 263.50M |
| KalVista Pharmaceuticals | 73.62M |
| Wave Life Sciences | 71.80M |
| Viridian Therapeutics | 70.85M |
| Immatics | 56.67M |
| Precigen | 9.68M |
| Maze Therapeutics | 2.50M |
IMCR News
- 15 days ago - KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma - GlobeNewsWire
- 21 days ago - Immunocore Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 4 weeks ago - Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting - GlobeNewsWire
- 2 months ago - Immunocore Holdings Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 2 months ago - Immunocore Holdings Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Immunocore reports fourth quarter and full year 2025 financial results and provides a business update - GlobeNewsWire